Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Understanding the role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
| Condition |
|---|
|
Respiratory Distress Syndrome, Adult |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS) |
| Estimated Enrollment: | 32 |
| Study Start Date: | January 2006 |
In previous lab experiments, we observed evidence of pulmonary edema following alveolar epithelial overexpression of VEGF, suggesting a potential role for VEGF in ARDS. In addition, we found that preventing VEGF from reaching its target receptor(s) by overexpressing a soluble form of a VEGF receptor protein prevents edema formation.
These observations heighten the plausibility of VEGF playing an important role in the development of increased pulmonary capillary permeability during acute lung injury. Understanding this role VEGF plays in ARDS consequently provides an ideal opportunity to discover new therapies for ARDS.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects for the study will be drawn from endotracheally intubated inpatients of The New York Presbyterian Hospital-Weill Cornell Medical Center diagnosed with ALI or ARDS or who are at risk for developing ARDS.
Inclusion Criteria:
- Patients that meet the American-European Consensus Conference criteria for ARDS [(1) Widespread pulmonary infiltrates; (2) Pulmonary capillary wedge pressure 18 mmHg; (3) PaOz/FiO; ratio 200; (4) compatible history], or acute lung injury [same as ARDS, but PaOz/FiOz ratio 300], or are at increased risk for developing acute lung injury because of sepsis, pancreatitis, trauma, acid aspiration, radiation or chemotherapy-induced lung toxicity, and near drowning. Pulmonary edema is divided into two broad categories: hydrostatic or cardiogenic and increased-permeability or noncardiogenic edema12. Since ARDS is noncardiogenic in origin, patients with pulmonary edema due to congestive heart failure will serve as a control group.
- Inpatients that are endotracheally intubated.
- Patients that are able to provide informed consent or informed consent is granted by a family member or legal health care proxy.
- Males or females that are 18 years or older.
Exclusion Criteria:
- Individuals who are too hypoxemic for bronchoscopy to be performed safely. Patients requiring V\0z > 0.7 and/or PEEP 15 will be excluded.
2. If the patient will be unable to tolerate bronchoscopy because of severe
acidosis, tension pneumothorax, active bronchospasm, hemodynamically significant cardiac arrhythmia, or intractable shock as defined as the inability to maintain a mean arterial pressure 60 mmHg or severe uncorrectable bleeding diathesis (tendency) or as otherwise determined by the pulmonary physician.
3. Females who are pregnant will not be accepted into the study. 4. Patients with recent (48 hours) acute myocardial infraction will not be accepted into the study.
5. Patients with a history of adverse reactions to lidocaine will be not be accepted into the study. 6. Patients who lack capacity to give informed consent due to acute panic attack, "intensive care unit" psychosis or other psychologic dysfunction.
Contacts and Locations| United States, New York | |
| Weill Medical College of Cornell University | Recruiting |
| New York City, New York, United States, 10021 | |
| Contact: Sandra Hyde 646-962-2672 sah2003@med.cornell.edu | |
| Principal Investigator: Robert J. Kaner, MD | |
| Principal Investigator: | Robert J. Kaner, M.D. | Weill Medical College of Cornell University |
More Information
No publications provided
| Responsible Party: | Dr. Robert J. Kaner, Weill Cornell Medical College, Department of Genetic Medicine |
| ClinicalTrials.gov Identifier: | NCT00319631 History of Changes |
| Other Study ID Numbers: | VEGF in ARDS |
| Study First Received: | April 27, 2006 |
| Last Updated: | February 18, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Weill Medical College of Cornell University:
|
Respiratory Distress Syndrome, Adult |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Lung Injury Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases |
Thoracic Injuries Wounds and Injuries Mitogens Endothelial Growth Factors Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 21, 2013